Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 7/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15746313 | 0.85 | AAK1 (0.74) | AAK1HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL15111081 | 0.76 | AAK1 (0.61) | AAK1HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL14315711 | 0.75 | AAK1 (0.60) | AAK1ALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL18508243 | 0.74 | AAK1 (0.59) | AAK1HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL7604703 | 0.74 | HDAC1 (0.63) | AAK1HDAC3HDAC1HDAC2GPR35 | |
| SCHEMBL17493751 | 0.72 | AAK1 (0.57) | AAK1HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL19719723 | 0.72 | AAK1 (0.56) | AAK1ALDH1A1GAAKMT2A | |
| SCHEMBL14690824 | 0.71 | AAK1 (0.55) | AAK1HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL2708564 | 0.70 | ALDH1A1 (0.58) | AAK1HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL25262360 | 0.70 | AAK1 (0.54) | AAK1ALDH1A1HPGDHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3177604-A1 | HETEROCYCLIC KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016022312-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016022312-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | AAK1, NCK1, DAPK2 | AAK1 1/4885HDAC3 2460/4885HDAC1 1770/4885 |
| US-10035777-B2 | Heterocyclic kinase inhibitors | AAK1, NCK1, DAPK2 | AAK1 1/4885HDAC3 2460/4885HDAC1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.